Literature DB >> 31161844

Management of cytokine release syndrome: an update on emerging antigen-specific T cell engaging immunotherapies.

Roman H Khadka1,2, Reona Sakemura3, Saad S Kenderian2,3, Aaron J Johnson2,4.   

Abstract

Keywords:  BiTE; CAR T cells; CRS; bispecific T cell engager; chimeric antigen receptor; cytokine release syndrome; immunotherapy; neurotoxicity

Mesh：

Year:  2019        PMID： 31161844     DOI： 10.2217/imt-2019-0074

Source DB:  PubMed          Journal:  Immunotherapy        ISSN： 1750-743X            Impact factor:   4.196


× No keyword cloud information.
  19 in total

1.  Clinical criteria for COVID-19-associated hyperinflammatory syndrome: a cohort study.

Authors:  Brandon J Webb; Ithan D Peltan; Paul Jensen; Daanish Hoda; Bradley Hunter; Aaron Silver; Nathan Starr; Whitney Buckel; Nancy Grisel; Erika Hummel; Gregory Snow; Dave Morris; Eddie Stenehjem; Rajendu Srivastava; Samuel M Brown
Journal:  Lancet Rheumatol       Date:  2020-09-29

Review 2.  State of the art in CAR T cell therapy for CD19+ B cell malignancies.

Authors:  Matthew J Frigault; Marcela V Maus
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

3.  GM-CSF disruption in CART cells modulates T cell activation and enhances CART cell anti-tumor activity.

Authors:  Michelle J Cox; Claudia Manriquez Roman; Reona Sakemura; Erin E Tapper; Elizabeth L Siegler; Dale Chappell; Cameron Durrant; Omar Ahmed; Sutapa Sinha; Raphael Mwangi; Nancy S Scott; Mehrdad Hefazi; Kendall J Schick; Paulina Horvei; Michael W Ruff; Ismail Can; Mohamad Adada; Evandro Bezerra; Lionel Aurelien Kankeu Fonkoua; Sameer A Parikh; Neil E Kay; Saad S Kenderian
Journal:  Leukemia       Date:  2022-04-19       Impact factor: 12.883

Review 4.  Reducing the Fatality Rate of COVID-19 by Applying Clinical Insights From Immuno-Oncology and Lung Transplantation.

Authors:  Fatih M Uckun
Journal:  Front Pharmacol       Date:  2020-05-26       Impact factor: 5.810

5.  Loading of Primary Human T Lymphocytes with Citrate-Coated Superparamagnetic Iron Oxide Nanoparticles Does Not Impair Their Activation after Polyclonal Stimulation.

Authors:  Marina Mühlberger; Harald Unterweger; Julia Band; Christian Lehmann; Lukas Heger; Diana Dudziak; Christoph Alexiou; Geoffrey Lee; Christina Janko
Journal:  Cells       Date:  2020-02-01       Impact factor: 6.600

Review 6.  Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf.

Authors:  Gregorio Barilà; Rita Rizzi; Renato Zambello; Pellegrino Musto
Journal:  Pharmaceuticals (Basel)       Date:  2021-01-07

7.  Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice.

Authors:  Hairuo Wen; Zhe Qu; Yujing Yan; Chengfei Pu; Chao Wang; Hua Jiang; Tiantian Hou; Yan Huo
Journal:  Ann Transl Med       Date:  2019-12

Review 8.  BiTEs, DARTS, BiKEs and TriKEs-Are Antibody Based Therapies Changing the Future Treatment of AML?

Authors:  Cecily Allen; Amer M Zeidan; Jan Philipp Bewersdorf
Journal:  Life (Basel)       Date:  2021-05-23

Review 9.  Concepts in immuno-oncology: tackling B cell malignancies with CD19-directed bispecific T cell engager therapies.

Authors:  Andreas Viardot; Franco Locatelli; Julia Stieglmaier; Faraz Zaman; Elias Jabbour
Journal:  Ann Hematol       Date:  2020-08-27       Impact factor: 3.673

Review 10.  Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.

Authors:  Marion Alcantara; Pauline Du Rusquec; Emanuela Romano
Journal:  Oncoimmunology       Date:  2020-06-10       Impact factor: 8.110
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.